China: Review VPEIF 2021 A Glimpse into the Growing Chinese Pharma Industry and Cutting-edge Technology
The Vogel Pharmaceutical Engineering International Forum (VPEIF) 2021 was successfully held on October 20-21 in Taizhou, China Medical City, China. Focusing on the latest trends in global pharmaceutical engineering, R&D, production, and quality management, the show comprised of one main session and five parallel sessions which were led by industrial experts and enterprises in the region.
Taizhou/China – The 13th edition of the Vogel Pharmaceutical Engineering International Forum (VPEIF) 2021 was successfully held on October 20-21 in Taizhou, China Medical City, China. The industry event has long been one of the fixed highlights in the calendar of the pharmaceutical industry in China. Organized by PharmaTEC China and Taizhou Medical Hi-tech Industrial Zone, and assisted by Tianjin University of Traditional Chinese Medicine, this year the forum witnessed the participation of 59 exhibitors and a footfall of almost 1,000 people making it a successful event. The number of participants, which was about one third lower than in the previous year, was due to the regional Corona conditions. The organizer PharmaTEC China also released a ‘Report on the Chinese Biopharmaceutical Industry 2020’ at the forum which elaborated on diverse subjects including the development and opportunities in the Chinese biopharmaceutical industry, an analysis of the innovation trends and investment opportunities of the Chinese biopharmaceutical industry, etc.
Export Delivery Value of the Pharmaceutical Manufacturing Industry Increased by 70 Percent
With the improvement of people's living standards and the aging of the population, the market has a strong demand for improvement of the production capacity and quality of pharmaceutical products. The opportunities for innovation and profitability of pharmaceutical companies are huge, and market growth is also stable.
According to data from the National Bureau of Statistics, in 2020, China's pharmaceutical manufacturing enterprises achieved an operating income of 345 billion euros (2485.73 billion yuan), an increase of 4.5 % year-on-year, and realized total profits of 49 billion euros (350.67 billion yuan), an increase of 12.8 % year-on-year.
In the first three quarters of 2021, driven by the strong demand for Covid-19 vaccines and anti-epidemic supplies, China's pharmaceutical manufacturing industry achieved strong growth, up 29.2 % year-on-year, and the two-year average growth rate was 15.4 %; the export delivery value of the pharmaceutical manufacturing industry increased by 70.2 %, continuing the rapid growth momentum since the second half of last year.
At the same time, in the first three quarters, fixed asset investment in the pharmaceutical manufacturing industry increased by 14.4 % year-on-year. In particular, the biopharmaceutical industry is ushering an outbreak. Among them, biosimilar drugs have reached 6.4 billion yuan in 2020 and are expected to reach 8 billion euros (59 billion yuan) in 2030. The expansion of Covid-19 vaccines production capacity prompts China's biopharmaceutical companies to increase fixed asset investment. This undoubtedly will bring benefits to the downstream pharmaceutical equipment industry.
With the rapid development of the industry, China's pharmaceutical industry needs to unswervingly implement new development concepts and adhere to the path of innovation and transformation in order to respond to the complex and changeable market environment and the increasing customized needs of the customers. Vogel Pharmaceutical Engineering International Forum, as a professional technology exchange and cooperation platform, always adheres to the tracking of hot topics in the industry, and is committed to sharing the latest trends in global pharmaceutical engineering, R&D, production, and quality management.
It also helps companies to stay updated on the latest international cutting-edge technologies and promote the high-end development of the industry. This year, the forum comprised of one main session and five parallel sessions where nearly 60 industrial experts and almost 60 enterprises were invited to give speeches and presentations. About 1,000 professionals from the entire pharmaceutical industry chain enjoyed the innovative and valuable audio-visual show.
VPEIF Guides the Enterprises to Follow International Cutting-edge Technology
At the main session, Zhou Baodong, Deputy Secretary of Party Committee of China Machinery Information Institute and Publication said, “As a professional industrial media organization, we not only need to help push forward the advances of the Chinese pharmaceutical process technology, and engineering and equipment technology, but also promote the industry to strengthen cooperation and exchanges. The forum through practical contents guided the enterprises to follow international cutting-edge technology which speeds up the development of internationally competitive new products, new technique and new equipment, and promotes high-end development of the industry.”
China is striving to transform from a big manufacturing country to a strong manufacturing power.
Gerd Kielburger, Director International Business & Strategy, Vogel Communications Group was unable to attend the event due to the pandemic; hence, he expressed his ideas via a video. He said, “Discussions about artificial intelligence or digitalization in the research, development, and production of medicines are at the forefront; and mRNA vaccines are currently on the rise and could combat many other diseases in the future. Thanks to state-of-the-art techniques and processes, it is impressive how quickly the global pharmaceutical industry can now develop and produce effective vaccines. The biopharmaceutical industry, in particular, is facing enormous growth potential. However, it is not uncommon to face problems with the application of GMP. The result is contaminated batches and all the associated legal and financial consequences or, not least, damage to the manufacturer's image.” He also pointed out that with rapid development, companies should also provide employees with more care and training on quality and efficiency.
Sun Xianze, Chairman of Chinese Pharmaceutical Association said in his speech that the development of the Chinese pharmaceutical industry is facing new situations, new requirements and new opportunities. Multilevel and diversified health needs of the masses are growing. Core technologies in the fields of drug, medical equipment, and medical treatment also needs to be settled urgently. In addition, the occurrence of Covid-19 highlights the importance and urgency of the development of the pharmaceutical industry even more. A series of national policies also promote the structural adjustment and technology upgrade of the pharmaceutical industry.
China Medical City as the organizer of the show provided strong support for the success of the forum. Chen Lei, member of Party Working Committee of Taizhou Medical Hi-tech Industrial Zone, believed that the forum would play an important role in supporting and promoting high-quality development of the pharmaceutical industry. He expressed in his speech that China Medical City has gradually grown, has preliminarily constructed a distinctive medical park featuring biologic drugs, complete industry chains, a sound technology platform and a professional service level. More than 1,200 pharmaceutical companies, including 13 world-famous multinational pharmaceutical manufacturers, are now based at the China Medical City.
As the representative of the co-organizer, Li Zheng, Dean of the College of Pharmaceutical Engineering of Traditional Chinese Medicine at Tianjin University of Traditional Chinese Medicine mentioned in his speech that China is striving to transform from a big manufacturing country to a strong manufacturing power. High-quality development of biologic drugs represents a part of the national comprehensive strength; therefore, we should think positively on how to improve high-end technology and how to train high-tech talents. He added that in the age of digital transformation, it is particularly important for pharmaceutical companies to make good use of artificial intelligence technologies and modern information.
New Report on the Chinese Biopharmaceutical Industry 2020
In recent years, the current situation and innovation trends of the Chinese biopharmaceutical industry have attracted much attention from the industry. Yang Qiong, Director of PharmaTEC China released a ‘Report on the Chinese Biopharmaceutical Industry 2020’ at the forum. She revealed that 10 experts from different pharmaceutical companies were invited to write the report. The report elaborates on diverse subjects including the present situation and the development of the Chinese biopharmaceutical industry, opportunities for the biopharmaceutical industry, an analysis of the innovation trends of the Chinese biopharmaceutical industry, the current market situation and the trends of the Chinese biopharmaceutical core equipment market, an analysis of the investment opportunities of the Chinese biopharmaceutical industry, etc. She pointed out that PharmaTEC China also plans to release reports on smart manufacturing, oral solid dosage, biosimilar, pharmaceutical packaging and other fields, thus delivering valuable information for the industry.
The cell therapy product market is one of the fastest growing subfields in the biologic drugs market right now. In the past ten years, China has made a series of important policies and regulations in the field of cell therapy. Since 2015, particularly in 2020, the development of cell therapy entered a stage of rapid development with the support of these policies.
Bi Jun, Licensing Review Center of Shenzhen Administration for Market Regulation elaborated in his speech about the particularity of cell therapy products in six aspects in terms of GMP; he spoke about the risk control strategy of manufacturing of cell therapy products in terms of system, training, manufacturing, decontamination measures, segregation requirements, standard requirements and other aspects; and comprehensively and meticulously interpreted the regulations on cell therapy products.
In addition, Wang Yinqing, Customer Support Manager of Fette Compacting (China), shared the topic of ‘Lifetime Efficiency-High-end Solution for OSD Production’ in his speech. He vividly explained what is lifetime efficiency through specific cases served by the company and put forward a method to efficiently increase the rate of return.
After the conclusion of the main session, the five well-organized separate sessions which focused on aseptic processing, biopharmaceutical engineering and equipment, biopharmaceutical process development and manufacturing, the oral solid dosage/botanical drugs, and the smart factory/process automation kicked off in parallel. These sessions attracted numerous players from the pharmaceutical industry.
In the five separate sessions, nearly 60 experts from the pharmaceutical industry introduced the latest trends and typical practice cases of the pharmaceutical industry to the audience, providing valuable guidance to the pharmaceutical industry. The speakers for these sessions were from well-known pharmaceutical companies, engineering companies and consulting companies, as well as representatives from well-known pharmaceutical equipment enterprises.
Transforming and upgrading the pharmaceutical industry will be a challenging task which will require the joint efforts of both the professionals and the experts in the pharmaceutical field.
We believe that China's pharmaceutical industry will develop even better under the guidance of experts and the joint efforts of all our colleagues in the industry. The Vogel Pharmaceutical Engineering International Forum has always been and will keep focusing on the development trends of global industries and the latest updates of technological creations from a global perspective, and advocate for industry reform with a prospective and innovative vision. The next VPEIF will most likely take place in September 2022. Location and venue will be announced as soon as possible.